Samsung Biologics Co.,Ltd. (207940.KS), a contract development and manufacturing organization, on Friday reported strong year-on-year growth in profit and revenue for the first quarter.
Net income from continuing operation before income tax rose 45.9% to KRW 640.593 billion from KRW 439.102 billion a year earlier.
Operating income increased to KRW 580.753 billion, compared with KRW 430.240 billion last year.
Net income attributable to shareholders of the parent company came in at KRW 469.245 billion, 41.6% up from KRW 331.333 billion a year earlier.
Sales grew 25.8% to KRW 1.2571 trillion from KRW 999.545 billion in the previous year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.